GlassScriptPhysician profile
James M Zasuly
NPI 1932120573
$600.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $84.39 · 2021: $61.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $205.48 | 2019-2021 | |
| Abbvie INC. | $90.31 | 2019-2021 | |
| Allergan, INC. | $72.31 | 2019-2020 | |
| Lilly USA, LLC | $44.25 | 2019 | |
| Galderma Laboratories, L.P. | $27.40 | 2019-2021 | |
| Janssen Biotech, INC. | $26.87 | 2019-2020 | |
| Celgene Corporation | $22.85 | 2019 | |
| Biofrontera INC. | $19.37 | 2019 | |
| Smith+Nephew, INC. | $18.09 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $16.41 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.67 | 2019 | |
| Endo Pharmaceuticals INC. | $15.15 | 2019 | |
| Kci USA, INC. | $14.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zasuly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.